<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Development of new TB regimens : harmonizing trial design, product registration requirements, and public health guidance</dc:title>
  <dc:creator>/Lienhardt, Christian</dc:creator>
  <dc:creator>Vernon, A. A.</dc:creator>
  <dc:creator>Cavaleri, M.</dc:creator>
  <dc:creator>Nambiar, S.</dc:creator>
  <dc:creator>Nahid, P.</dc:creator>
  <dc:description>Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.</dc:description>
  <dc:date>2019</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010077108</dc:identifier>
  <dc:identifier>fdi:010077108</dc:identifier>
  <dc:identifier>Lienhardt Christian, Vernon A. A., Cavaleri M., Nambiar S., Nahid P.. Development of new TB regimens : harmonizing trial design, product registration requirements, and public health guidance. 2019, 16 (9),  e1002915 [13 p.]</dc:identifier>
  <dc:language>EN</dc:language>
  <dc:coverage>MONDE</dc:coverage>
</oai_dc:dc>